-The Times of India Big pharma may be crying hoarse over India's "weak'' intellectual property environment, but over the past five years or so, they have introduced only a handful of their patented blockbusters in the country. That's not all. The contribution of patented drugs in the Rs 72,000-crore pharma retail market is not even 1%, indicating that multinationals have been traditionally slow and have a poor track record in introducing...

-The Hindu THIRUVANANTHAPURAM: Dengue, the world's most rapidly spreading mosquito-borne viral disease, is taking a far bigger human toll than was believed to be the case. As many as 390 million people across the globe could be falling victim to the virus each year, according to a multinational study published by Nature on Sunday. India emerges in the analysis as the country with the world's highest dengue burden, with about 34 per...

-The Hindu   Entering third polio-free year, India must destroy all wild poliovirus lab samples by December Having successfully completed two polio-free years, India is preparing to receive the crucial polio eradication certificate from the World Health Organisation (WHO). The certificate is issued on completion of incident-free three years. This primarily involves the destruction or safe storage of all laboratory sources of wild poliovirus. The storage should be in laboratories that meet international standards...

-The Hindu     Drug patents are designed to create profits that enable more Research on diseases affecting millions. But in practice, they have often generated super profits for big pharma companies while erecting access barriers for the poor. The Novartis case spotlights much that is wrong with the system. The rejection of the Novartis petition challenging one of the most progressive tenets of the Indian Patents Act (1970), as amended in 2005 by...

-The Hindu Well before the Supreme Court rejected Novartis' application for patent for Glivec (Gleevec in the U.S.), drawing attention to the dichotomy of generic and patented drugs, activists have been demanding access to expensive drugs used in the treatment of cancer, hepatitis C and serious HIV. Trastuzumab is one such, used in the treatment of HER2+ type of breast cancer, which affects about one in four patients with the disease. Rough...